Aygun H, Gul S S
Bratisl Lek Listy. 2019;120(4):249-255. doi: 10.4149/BLL_2019_045.
The present study aimed to determine the protective effect of melatonin and agomelatine on DOX-induced cardiotoxicity in rats by electrocardiographic, scintigraphic and biochemical methods.
Forty-nine male Wistar rats were randomly separated into seven groups; control (CON), doxorubicin (DOX), melatonin (MEL), agomelatine (AGO), melatonin+doxorubicin (MEL+DOX), agomelatine+doxorubicin (AGO+DOX) and melatonin+ agomelatine+ doxorubicin (MEL+AGO+DOX) groups. Cardiotoxicity was induced by intraperitoneal (i.p.) injection of DOX (18 mg/kg daily for three days). Rats receiving MEL and AGO treatment in the DOX-induced cardiotoxicity group received MEL and AGO (40 mg/kg/day, i.p., for seven days). They were injected with doxorubicin (18 mg/kg, i.p.) on days 5, 6, and 7. The rats were given MEL and AGO as substance control (40 mg/kg/day, i.p., for 7 days). On day 8 of the experiment, animals were evaluated by means of electrocardiography (ECG) and 99mtechnetium pyrophosphate (99mTc PYP) scintigraphy and their biochemical parameters [blood urea nitrogen (BUN), creatine kinase (CK), cardiac troponin T (cTnT)] were examined.
DOX-induced acute cardiotoxicity in rats is characterized by conduction abnormalities in the ECG pattern (including decreased P wave and QRS complex duration, increased QT and RR intervals, and ST-segment elevation), increased serum BUN, CK, and cTnT parameters and increased 99mTc PYP uptake (p < 0.001). Pretreatment with MEL, AGO, or MEL+AGO effectively alleviated DOX-induced ECG abnormalities close to normal (p < 0.001). Moreover, serum biochemical evidence and 99mTc PYP uptake values demonstrated that pretreatment with MEL, AGO, or MEL+AGO has the same protective effect against the abnormalities produced in the heart by DOX (p < 0.001).
MEL and AGO have a potential protective effect on DOX-induced cardiotoxicity. At the same time, this study suggests that 99mTc PYP is a non-invasive method suitable for early determination of DOX-induced cardiotoxicity (Tab. 3, Fig. 5, Ref. 41).
本研究旨在通过心电图、闪烁扫描和生化方法确定褪黑素和阿戈美拉汀对阿霉素诱导的大鼠心脏毒性的保护作用。
49只雄性Wistar大鼠随机分为7组;对照组(CON)、阿霉素组(DOX)、褪黑素组(MEL)、阿戈美拉汀组(AGO)、褪黑素+阿霉素组(MEL+DOX)、阿戈美拉汀+阿霉素组(AGO+DOX)和褪黑素+阿戈美拉汀+阿霉素组(MEL+AGO+DOX)。通过腹腔注射阿霉素(18mg/kg,每日一次,共三天)诱导心脏毒性。在阿霉素诱导的心脏毒性组中接受MEL和AGO治疗的大鼠接受MEL和AGO(40mg/kg/天,腹腔注射,共七天)。在第5、6和7天给它们注射阿霉素(18mg/kg,腹腔注射)。给大鼠注射MEL和AGO作为物质对照(40mg/kg/天,腹腔注射,共7天)。在实验的第8天,通过心电图(ECG)和99m锝焦磷酸盐(99mTc PYP)闪烁扫描对动物进行评估,并检查其生化参数[血尿素氮(BUN)、肌酸激酶(CK)、心肌肌钙蛋白T(cTnT)]。
阿霉素诱导的大鼠急性心脏毒性的特征是心电图模式出现传导异常(包括P波和QRS复合波持续时间缩短、QT和RR间期延长以及ST段抬高)、血清BUN、CK和cTnT参数升高以及99mTc PYP摄取增加(p<0.001)。用MEL、AGO或MEL+AGO预处理可有效缓解阿霉素诱导的心电图异常,使其接近正常(p<0.001)。此外,血清生化证据和99mTc PYP摄取值表明,用MEL、AGO或MEL+AGO预处理对阿霉素引起的心脏异常具有相同的保护作用(p<0.001)。
MEL和AGO对阿霉素诱导的心脏毒性具有潜在的保护作用。同时,本研究表明99mTc PYP是一种适用于早期确定阿霉素诱导的心脏毒性的非侵入性方法(表3,图5,参考文献41)。